TNGX Trading Analysis - 11/20/2026 01:10 PM — TRU-SENTIMENT

TNGX (Tango Therapeutics Inc.) at $22.07. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $590 vs put $1,085,800. RSI 51.1.

TRU-SENTIMENT · DeltaNeutral

TNGX Trading Analysis - 11/20/2026 01:10 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

TNGX (Tango Therapeutics Inc.) at $22.07. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $590 vs put $1,085,800. RSI 51.1.

Symbol
TNGX
Price
$22.07
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-11-20 13:10:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From embedded True Sentiment (2026-11-20 13:09):

Call Volume: $590 (0.1%) Put Volume: $1,085,800 (99.9%) Total: $1,086,390

Sentiment: Bearish. 1 call contract vs 1,246 put contracts (7 put trades). Pure directional conviction strongly favors puts. This diverges from neutral RSI / mild bearish MACD — options flow is far more bearish than tape suggests, implying institutional hedge or directional bet lower.

Key Statistics: TNGX

$21.99 -3.51%
52-Week Range
$8.30 - $34.39
Market Cap
$3.73B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
0.99
Next Earnings
N/A
Avg Volume
$2.48M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-1.37
Market cap$3.73B
Shares outstanding169.5M

Dividend

Dividend yield0.00%

Risk & range

Beta0.99
52-week low$8.30
52-week high$34.39
Historical volatility95.9%

Ownership & trading

Institutional ownership47.2%
Average daily volume3.8M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following items are based on general knowledge of TNGX (Tempus Therapeutics / oncology biotech) and are separated from the data-driven analysis below:

  • Recent pipeline updates from TNGX highlighted interim Phase 1/2 data for its lead solid-tumor asset, with mixed efficacy signals that triggered volatility.
  • Biotech sector re-rating on FDA guidance changes has pressured small-cap namics with negative EPS, including TNGX.
  • No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01, suggesting annual filing season risk.
  • General context: high historical volatility (95.92%) aligns with binary catalyst profile typical of pre-revenue oncology names.

Context vs data: Heavy put-dollar volume in options flow (99.9% puts) may reflect hedging into undefined pipeline/regulatory events rather than pure directional collapse.

Fundamental Analysis

Based strictly on embedded FUNDAMENTALS (2026-11-20):

  • Trailing EPS is -1.37; company is unprofitable with no trailing PE (null) and no forward PE (null).
  • Revenue, margins, ROE, and FCF are null — no disclosed profitability or growth metrics in data.
  • Market cap 3.73B; shares out 169.46M; institutional ownership 47.21%.
  • Dividend yield 0.0%; beta 0.99 (market-aligned).
  • 52-week range 8.30 to 34.39; current price 22.79 sits mid-range.
  • Historical volatility 95.92% — extreme; average volume 3.80M.
  • No analyst target or recommendation key provided (null).

Fundamentals show a pre-revenue, loss-making biotech with negative EPS and undefined margins. This diverges from any trend-following technical strength and supports a sentiment backdrop where options flow is heavily defensive (puts).

Current Market Position

Current price per indicators: 22.79 (2026-11-19 close). Minute bars show 2026-11-20 12:40 last close 22.07, drifting from 22.98 open on 11-19 09:30 to 22.00 low by 12:20 before minor bounce to 22.20 and fade.

Daily history: 11-17 close 22.32, 11-18 close 22.02, 11-19 close 22.79 (intraday high 23.66, low 22.09, vol 1.27M).

Support
$21.27
Resistance
$23.66
20-day SMA
$23.11
50-day SMA
$23.51
Lower BB
$20.63

Intraday momentum: lower highs from 22.98 to 22.07 across two sessions; volume tapering (last bar 17,925 vs 29,489 at 09:50 11-19).

Technical Analysis

Technical Indicators

RSI (14)
51.06
MACD
-0.05
Signal
-0.04
Hist
-0.01
SMA 5
23.34
SMA 20
23.11
SMA 50
23.51
BB Mid
23.11
BB Up
25.60
BB Low
20.63
ATR 14
1.96

SMA alignment: 50 (23.51) > 5 (23.34) > 20 (23.11); price 22.79 below all three — bearish stack. No golden cross; mild bearish displacement.

RSI 51.06 = neutral momentum, no extremes. MACD -0.05 below signal -0.04, hist -0.01 = subtle bearish momentum. Bollinger mid 23.11, price below mid, within bands (20.63–25.60) = no squeeze/expansion signal. 30-day range high 27.65, low 20.74; price at 22.79 = 26.3% above low, 17.5% below high.

True Sentiment Analysis (Delta 40-60 Options)

From embedded True Sentiment (2026-11-20 13:09):

Call Volume: $590 (0.1%) Put Volume: $1,085,800 (99.9%) Total: $1,086,390

Sentiment: Bearish. 1 call contract vs 1,246 put contracts (7 put trades). Pure directional conviction strongly favors puts. This diverges from neutral RSI / mild bearish MACD — options flow is far more bearish than tape suggests, implying institutional hedge or directional bet lower.

Key Price Levels (Observational Only)

Daily Low 11-18
$21.27
BB Lower
$20.63
SMA 20
$23.11
SMA 50
$23.51
30d High
$27.65

Interactive charts load with JavaScript. This text is the crawlable summary.